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Telomere homolog oligonucleotides (T-oligos) activate an innate telomere-based program that leads to multiple anticancer effects.
T-oligos act at telomeres to initiate signaling through the Werner protein and ATM kinase. We wanted to determine if T-oligos
have antiangiogenic effects. We found that T-oligo-treated human melanoma (MM-AN) cells had decreased expression of vascular
endothelial growth factor (VEGF), VEGF receptor 2, angiopoeitin-1 and -2 and decreased VEGF secretion. T-oligos activated
the transcription factor E2F1 and inhibited the activity of the angiogenic transcription factor, HIF-1α. T-oligos inhibited EC
tubulogenesis and total tumor microvascular density matrix invasion by MM-AN cells and ECs in vitro. In melanoma SCID
xenografts, two systemic T-oligo injections decreased by 60% (P < .004) total tumor microvascular density and the functional
vessels density by 80% (P < .002). These findings suggest that restriction of tumor angiogenesis is among the host’s innate
telomere-based anticancer responses and provide further evidence that T-oligos may offer a powerful new approach for melanoma
treatment.
1. Introduction
Angiogenesis, the formation of new blood vessels, is essential
for tumor growth and metastasis [1] and inhibition of
angiogenesis is an important new approach for therapy of
many cancers [1, 2]. A principal regulator of angiogenesis is
vascular endothelial growth factor (VEGF) [3]. The VEGF
family is comprised of at least five genes (VEGF A through
E), of which the most potent activators of angiogenesis are
VEGF-A and VEGF-B [4]. Analysis of the VEGF-A (termed
VEGF here and elsewhere in the text) gene promoter region
has revealed numerous potential transcriptional activator
sites [4]. One of the best studied stimuli for VEGF synthesis
and secretion is hypoxia, which acts by upregulating hypoxia
inducible factor-1α (HIF-1α) [5]. Inhibition of HIF-1α
may therefore decrease angiogenesis by reducing VEGF
levels and potentially other proangiogenic factors, such
as angiopoeitin-1 and -2 (Ang-1 and Ang-2) [6–8], basic
fibroblast growth factor (bFGF), and platelet derived growth
factor (PDGF), all well known regulators of angiogenesis [1].
The role of E2F1 in apoptosis is well recognized. It can
act in concert with p53 or independent of p53 to induce
apoptosis [9]. T-oligos, telomere homolog oligonucleotides,
activate p53 and E2F1, resulting in apoptosis [10]. However,
in p53 null cells like malignant melanoma AN cells (MM-
AN), apoptosis is induced by the p53 homolog p73 [11],
presumably acting coordinately with E2F1. Moreover, E2F1
has also been reported to inhibit angiogenesis [9, 12]. While
E2F1 decreases VEGF production in fibroblasts through p53
activation [12], its effect on angiogenesis in cells that lack
functional p53, such as MM-AN cells has not been studied
[11, 13].
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Several lines of evidence suggest that normal cells have
an integrated program of genome-protective responses,
functionally analogous to the bacterial SOS response [14],
that is based in the telomeres and appears to be abrogated
in malignancy [15]. Telomeres, the ends of chromosomes, are
maintained in a loop configuration by insertion of the single-
stranded 3′ overhang into the proximal telomere duplex [16].
Disruption of this loop structure by removal of the principal
binding protein TRF2 (telomere repeat binding factor 2)
leads to exposure and digestion of the overhang and activa-
tion of ATM (ataxia telangiectasia mutated) and its effector
protein p53, followed by apoptosis or senescence, depending
on cell type [16]. Knockdown of another telomere-associated
protein, the protection of telomeres-1 (POT-1), also expected
to expose the TTAGGG telomere repeat sequence, activates
ATR (ataxia telangiectasia and Rad3-related), leading to
similar downstream effects [16, 17]. Moreover, treatment
of malignant cells with RNAi to knockdown the expression
of TER, the RNA subunit of telomerase, rapidly alters the
expression of many genes in a pattern predicted to reduce
cancer cell proliferation and invasiveness [18], then leads to
apoptosis in a time course far too rapid to be attributable
to the expected loss of telomerase activity and consequent
telomere shortening, suggesting that other telomere-based
effects are responsible [18].
Our laboratory has described several anticancer proper-
ties of oligonucleotides homologous to the telomere repeat
sequence TTAGGG (T-oligos) [10, 11, 13, 15, 19–28]. T-
oligos provided to cultured cells rapidly accumulate in
the nucleus and mediate DNA damage responses without
digestion of the telomere overhang or other detectable effects
on genomic DNA [10, 13, 15, 19, 23, 25, 26, 29]. T-
oligos activate the ATM kinase [21, 27], upregulate and
activate p53 [30, 31], as well as upregulate and/or activate its
homolog p73, E2F1, p16INK4a, p33, p27, and p95/Nbs1, and
phosphorylate the histone variant protein H2AX [11, 13, 21,
22, 24, 25]. In addition, T-oligos promote differentiation of
melanoma cells and downregulate the inhibitor of apoptosis
protein IAP/livin in these cells [13]. T-oligo effects require
WRN [22], the protein mutated in the progeroid cancer-
prone Werner syndrome [32], and are associated with
formation of classic DNA damage foci at telomeres [22].
In combination, these signaling cascades result in induction
of apoptosis, autophagy, and/or senescence selectively in
cancer cells [13, 19, 27, 28]; while in normal cells they
lead to transient cell cycle arrest, increased DNA repair
capacity and adaptive differentiation [19, 21, 23, 25–27, 30].
Complementary, unrelated, or scrambled oligonucleotides
comparably accumulate in the nucleus, but do not cause
DNA damage-like signaling or affect growth, differentiation
or survival of malignant cells [11, 13, 15, 19, 21, 24, 27, 28].
Because the T-oligo-induced transcription factors p53,
p73, and E2F1 are known to affect endothelial cell (EC)
survival, differentiation, and proliferation during tumor
angiogenesis [12, 33, 34] and because blocking angiogenesis
would be an additional anticancer mechanism of action for
T-oligos, we asked whether T-oligo treatment inhibits tumor
angiogenesis. We now report that T-oligo inhibits angiogen-
esis in the aggressive human melanoma cell line MM-AN,
derived from a metastatic melanoma [35], by decreasing
production and secretion of proangiogenic factors in both
tumor cells and ECs. As well, T-oligo treatment decreases the
number of total and functional (perfused) vessels in flank
tumors of MM-AN cells in SCID mice after two systemic
injections.
2. Materials and Methods
2.1. Cell Cultures. Human microvascular endothelial cells
(HMVECs) and human umbilical vein endothelial cells
(HUVECs) were obtained at passage 2 and used by passage
4–6. Cells were maintained in EGM-2 medium with 2%
FBS plus growth factors (bullet kit) (Cambrex Bio Sciences,
Walkersville, MD). Human melanoma MM-AN and EP cells
[35] were cultured in modified Eagle’s medium (MEM)
(Mediatech, Inc., Herndon, VA) supplemented with fetal
bovine serum (FBS 2%), calf serum (CS 8%), and antibiotic-
antimicotic. Human breast adenocarcinoma (MCF-7) and
ovarian adenocarcinoma (OVCAR3) cells were cultured and
maintained according to ATCC recommendations. All cells
were incubated at 37◦ with 5% CO2.
2.2. Oligonucleotides. We used a 16-base 100% telomere
homolog with the sequence 5′-GTTAGGGTTAGGGTTA-
3′ and phosphodiester backbone. The oligonucleotide was
synthesized by Midland Certified Reagent (Midland, TX) and
then diluted from a 2 mM stock in medium to obtain a final
concentration of 40 μM.
2.3. Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR). MM-AN, EP, MCF-7, and OVCAR3 cells were grown
in their corresponding media and treated once with dilu-
ent or 40 μM T-oligo. For qRT-PCR, we performed a
reverse transcription reaction then amplified specific genes
as described [36]. mRNA expression levels were assessed
for E2F1, ANG-1, and ANG-2. The sequences used were
as follows: E2F1 forward: CGGTGTCGTCGACCTGAACT,
E2F1 reverse: AGGACGTTGGTGATGTCATAGATG, E2F1
probe: TGCCGAGGTGCTGAAGGTGCAG; ANG-1 for-
ward: CAGAAAACAGTGGGAGAAGATATAACC, ANG-
1 reverse: TGCCATCGTGTTCTGGAAGA, ANG-1 probe:
CAACATGGGCAATGTGCCTACACTTTC; ANG-2 for-
ward: GGCTGGGCAATGAGTTTGTC, ANG-2 reverse:
CCCAGTCCTTCAGCTGGATCT; ANG-2 probe: ACC-
GGTCAGCACCGCTACGTGC.
2.4. Electromobility Shift Assay (EMSA). Cells were treated
with diluent or 40 μM T-oligo and harvested 0, 1, 16, and 32
hours after treatment. EMSAs were carried out as described
[10] using a total of 5 μg of nuclear protein per lane. The
assay was performed using consensus sequences of E2F1
and HIF-1α transcription factors (Santa Cruz Biotechnology,
CA). The specificity of the bands was confirmed by using
either ×25 or ×50 excess of cold probe as competitor and
mutant oligos as control. As an additional negative control,
nuclear extracts were incubated with a specific competing
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E2F1 antibody before adding the radioactive (32P-labelled)
consensus oligonucleotides.
2.5. Western Blot Analysis. Cells were treated with T-oligos,
harvested at various times, snap-frozen, and stored at−70◦C.
Total cellular protein was isolated and 50 μg of total protein
was processed for western blot analysis as described [10].
Antibody reactions were performed with the following anti-
bodies: anti-E2F1 (Neomarkers, Inc., Fremont, CA), anti-
VEGF-A (sc-507, Santa Cruz Biotechnology, Inc, Santa Cruz,
CA) that recognizes all VEGF-A isoforms, and anti-VEGF-
R2 (a kind gift from Dr. Nader Rahimi, Departments of
Ophthalmology and Biochemistry, Boston University School
of Medicine).
2.6. VEGF Enzyme-Linked Immunosorbent Assay (ELISA).
The Human VEGF Immunoassay kit (Quantikine, R&D
Systems, Minneapolis, MN) was used to compare the release
of VEGF into the medium by ECs and MM-AN cells. Each
cell type was cultured in its appropriate medium and treated
with either diluent or T-oligo (40 μM). The conditioned
medium was collected at 24, 48, and 72 hours after treatment
and frozen at −70◦C until it processed for ELISA. The assay
was performed according to the manufacturer’s protocol
(R&D Systems). The plate was read using the Tecan Spectra
model 96 Well Microplate Reader (MTX Lab Systems,
Vienna, VA).
2.7. Tubulogenesis Assay. 200 μL of Matrigel basement mem-
brane matrix (phenol-red free) (BD Biosciences, Bedford,
MA) was added per 4-well chamber slide and allowed to
solidify for 1 hour at 37◦C. HUVECs (50,000 cells) were then
added to each chamber in 500 μL of medium as described
[37]. Cells were treated at the time of plating with diluent,
40 μM, 80 μM, or 120 μM of T-oligo. Some of the cells treated
with 40 μM of T-oligo were retreated a second time at 2
hours postplating, at the time tube-formation could first be
detected by phase microscopy. Some cells that were treated
twice with 40 μM of T-oligo received a third treatment
6 hours after plating. Tube-formation was observed and
photographed at numerous time points starting from 2 hours
and up to 24 hours after treatment. Of note, after tubular
structures formed in control wells, they stayed intact up to
72 hours (data not shown). Image-Tool (The University of
Texas Health Science Center in San Antonio, San Antonio,
TX) software was used to quantify the length of tubular
structures.
2.8. Invasion Assay. The BioCoat Matrigel Invasion Chamber
(BD Biosciences, Bedford, MA) was used for this assay.
MM-AN cells were treated with diluent or 40 μM T-oligo
and media were collected after 72 hours, based on ELISA
data (MM-AN conditioned media). Conditioned MM-AN
medium was then used as the chemoattractant for the assay.
ECs and MM-AN cells were grown on the inserts (upper
chambers) and allowed to invade through the Matrigel and
attach to the membrane as described in the manufacturer’s
protocol. Invasion was assessed after 22 hours by staining
with Diff-Quick (Fisher, Atlanta, GA) bisected membranes
from the bottom of the chambers (containing the invading
cells) as described in the manufacturer’s protocol. Of note,
we believe that any effect on ECs or MM-AN invasion cannot
be attributed to residual active T-oligos in the conditioned
medium, diffusing into the upper chamber and killing MM-
AN cells, because T-oligos are rapidly degraded in serum-
containing medium. With a measured half-life for a 12-base
telomere homolog of 4–6 hours [38], the 16-base T-oligo
would thus have been present in the medium after 72 hours
of conditioning at an estimated (1/2)12 or 107-fold less than
the initial therapeutic concentration.
2.9. SCID Melanoma Flank Xenograft Model. All studies
were approved by Boston University’s IACUC Committee.
2 × 106 MM-AN cells were injected subcutaneously into the
flank of 6 week old SCID mice (Fox-Chase Cancer Center,
Philadelphia, PA). Mice (5-6 per treatment group) were
injected via tail vein with T-oligo or diluent alone when
tumors were first palpable (2-3 mm diameter). Tumor sizes
were recorded every 2-3 days throughout the experiment
using electronic callipers and all animals were sacrificed 4
weeks after tumor inoculation. The diagnosis of melanoma
was confirmed histologically on sections of each nodule cut
through the center of the clinical tumor.
2.10. Quantification of Tumor Microvessel Density. All studies
were approved by Boston University’s IACUC Committee.
2 × 106 MM-AN cells were injected subcutaneously into
the flank of 6 week old SCID mice (Fox-Chase Cancer
Center, Philadelphia, PA). Then mice (5-6 per treatment
group) were injected via the tail vein with T-oligo or
diluent alone (60 nmoles/injection, 15 mg/kg) when tumors
were first palpable (2-3 mm diameter). Microvascular density
(MVD) in bisected tumors were assessed 24 hours after
two systemic injections of T-oligos by using two EC-specific
markers CD31 (PECAM-1) [12] and Bandeurea simplicifolia
(BS)-1 lectin conjugated to Rhodamine (Vector Laboratories,
Burlingame, CA) [39]. To measure functional MVD in
the tumor tissue, 30 minutes before sacrifice a set of
mice (5 per treatment group) were anesthetized and were
perfused with 0.5 mg (in 100 μl of isotonic solution) of
Rhodamine-conjugated BS-1 lectin as described [40, 41]. To
measure total MVD, 6 μm cross-sections of bisected tumor
tissue (of the same mice perfused with BS-1 lectin) were
stained with CD31 primary antibody followed by FITC-
labelled secondary antibody as described [12]. Samples were
photographed using a multicolour fluorescence microscope
(Nikon, Nikon Instruments Inc, Melville, NY), and analyzed
using a digital image analysis system (Nikon). The diagnosis
of melanoma was confirmed histologically in tumor sections
of each nodule.
2.11. Statistical Analysis. ANOVA with post hoc analysis
by Scheffe and Bonferroni-Dunn and unpaired t-Test were
performed using StatView (SAS Institute, Inc., Version 5.0).
Statistical significance was established at P < .05.
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Figure 1: T-oligo treatment down-regulates expression of VEGF, Ang-1, Ang-2 and decreases VEGF production in MM-AN cells. MM-AN
cells were treated once at time 0 with either 40 μM T-oligo or diluent alone. (a) Western blot analysis of VEGF protein level. (b) Densitometric
analysis of VEGF protein levels (after loading adjustment against actin expression) represented as a percent of time 0 level. Graphs represent
pooled data (mean ± SEM) from three independent experiments. (c) and (d) Quantitative real time-PCR (qRT-PCR) of MM-AN cells
treated with either 40 μM T-oligo or diluent alone. Results are presented as percent of time 0 (set at 100%) and examined over 48 hours for
both control and T-oligo-treated cells. ANG-1 gene expression. (c) ANG-2 gene expression. (d) These experiments are repeated twice with
similar results. (e) MM-AN cells were treated with 40 μM T-oligo or diluent alone. The culture medium was collected after 24, 48, and 72
hours. Cumulative VEGF protein released into the medium was measured by ELISA. Results represent data pooled from triplicate dishes for
each time point and treatment condition. Changes over time are calculated as percent of the 24 hours values (set at 100%).
3. Results
3.1. T-oligo Treatment Decreases the Expression and Level of
Angiogenic Factors and Reduces VEGF Release into MM-AN
Cell Medium. MM-AN cells were treated once with T-oligo
or diluent alone, provided in fresh medium, and processed
for western blot analysis. Compared to diluent, T-oligo
decreased VEGF protein level at 24 hours (P < .01) by ∼41%
and at 48 hours (P = NS) by ∼32% (Figures 1(a) and 1(b)).
In addition, after 48 hours T-oligo treatment reduced ANG-1
mRNA (P < .01) by ∼60% (Figure 1(c)) and ANG-2 mRNA
(P < .04) by ∼45% (Figure 1(d)). Similar decreases in VEGF
(Supplemental Figures 1(a)–1(c) and ANG-1 (Supplemental
Figures 2(a)–2(c)) mRNA were seen in a second human
melanoma line EP, as well as in other malignant cell types.
Paired dishes of MM-AN and ECs were treated with
40 μM T-oligo or diluent alone once. Medium was collected
after 24, 48 and 72 hours and VEGF level in the medium
was measured by ELISA. In ECs (HMVEC and HUVEC),
there was a∼50%–75% variable and statistically insignificant
decrease in VEGF release into the medium over time in
both diluent- and T-oligo-treated cells (data not shown).
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In contrast, total VEGF release from MM-AN cells in
diluent-treated dishes rose progressively over 72 hours to
∼600% (of 24-hours VEGF levels), while VEGF release in
T-oligo-treated dishes was decreased (P < .0008) by ∼30%
over the 72-hours experiment after a single dosing at time
0 (Figure 1(e)). Thus, T-oligo not only decreased VEGF
protein expression in tumor cells but also the release of
this potent angiogenic factor into the surrounding culture
medium.
3.2. T-oligo Upregulates E2F1 Gene Expression, Protein Level,
and DNA Binding Activity and Decreases the DNA Binding
Activity of the Angiogenic Transcription Factor HIF-1α. E2F1
mRNA expression was increased at 24 hours (P < .0001) by
∼41% and at 48 hours (P < .0001) by ∼100% in T-oligo-
treated MM-AN cells compared to control (Figure 2(a)).
Similar increases in E2F1 mRNA were seen in a second
human melanoma line EP, as well as in other malignant cell
types (Supplemental Figures 3(a)–3(c)). T-oligo treatment
also increased E2F1 protein level at 24 hours to ∼218% and
at 48 hours to ∼286% (P < .02) of control values (Figures
2(b) and 2(c)). In addition, there was a doubling in E2F1
DNA binding activity 32 hours after treatment compared to
diluent-treated cells (Figures 2(d) and 2(e), compare lane 3
versus 4).
MM-AN cells were treated once with T-oligo or diluent
alone and nuclear proteins were harvested up to 32 hours
after treatment to evaluate DNA binding activities of the
angiogenic transcription factor HIF-1α. There was ∼80%–
95% decrease in HIF-1α DNA binding activity at 1 and 16
hours after treatments (Figures 2(f) and 2(g), lanes 3 versus
4, and 5 versus 6, respectively). These data suggest that T-
oligo-mediated inhibition in DNA binding activity of HIF-
1α transcription factor contributes to decreased expression of
the angiogenic factors, VEGF and ANG-1, whose promoters
contain binding sites for HIF-1α [42].
3.3. T-oligo Inhibits Matrigel Invasion by Melanoma Cells and
ECs. We used MM-AN medium collected 72 hours after
addition of T-oligo or diluent alone (MM-AN conditioned
media: T-oligo CM or diluent CM) as the chemoattractant
for an in vitro invasion assay [43]. MM-AN and HMVECs
were both evaluated for invasion through Matrigel to
determine if T-oligo treatment reduces the chemoattractant
properties of MM-AN cells. As recommended by the man-
ufacturer of the Matrigel invasion kit, after 22 hours of
incubation the invading cells were fixed, stained and counted
for each membrane. MM-AN cells plated above T-oligo CM
had a ∼96% decrease in invasion (P < .03) through Matrigel
(Figures 3(a) and 3(b)). HMVECs plated on inserts coated
with Matrigel and exposed to T-oligo CM had a ∼40%
reduction in Matrigel invasion compared to controls, but
this did not reach statistical significance (P < .08) (Figures
3(c) and 3(d)). These findings demonstrate that T-oligos
reduce the migration/invasion of MM-AN cells towards
chemoattractant stimuli and, possibly, to a lesser degree
affect HMVECs. This is consistent with the observation
that MM-AN cells elaborate factors that promote migration
and invasion of tumor cells, like VEGF and ANG-1, and
that these factor(s) are reduced as a result of T-oligo
treatment.
3.4. T-oligo Treatment Decreases the Expression of VEGF
and VEGFR-2 in Endothelial Cells. Because VEGF signal-
ing through VEGFR-2 is principally responsible for EC
survival, proliferation, migration, and angiogenesis [44–
47], we examined the effect of T-oligo treatment on these
proteins. HMVECs and HUVECs were grown and treated
with 40 μM T-oligo or diluent alone. Compared to diluent-
treated control cells there was a decrease (P < .004) of
∼86% in VEGF expression at 24 hours and an insignificant
decrease of ∼50% at 48 hours in T-oligo-treated samples
(Figures 4(a)–4(c)). In addition, in T-oligo-treated HMVECs
and HUVECs there were ∼29% (P = NS) and ∼59% (P <
.04) reduction in the protein level of VEGFR-2 at 24 and
48 hours, respectively (Figures 4(d)–4(f)). Thus, T-oligo-
mediated antiangiogenic effects on ECs may be, in part, due
to inhibition of VEGF-VEGR2 axis.
3.5. T-oligo Inhibits EC Function In Vitro in Tubulogenesis
Assay. HMVECs were plated on Matrigel in 4-well chamber
slides in serum-containing medium and treated with diluent
alone or increasing concentrations of T-oligo. Tube-like
structure formation was maximal in controls at 22 hours
and formal comparisons were made after 2–22 hours, as
customary for this assay [39]. By 22 hours, in cells treated
once with either 40 μM or 80 μM T-oligo there was a ∼
19% reduction in average tube length compared to cells
treated with diluent alone (P = NS) (Figures 5(a) and
5(b)). Cells treated with two separate doses of 40 μM T-
oligo at plating and 2 hours after plating showed a ∼35%
reduction in average tube length (P < .03). Cells treated once
at plating with 120 μM T-oligo showed a ∼58% reduction
in average tube length compared to the diluent-treated cells
(P < .001). A reduction of ∼83% (P < .0001) in tube
length was observed in cells treated with 3 separate doses
of 40 μM T-oligo (40 μM ×3) added to the medium at the
time of plating and then at 2 and 6 hours (Figures 5(a)
and 5(b)). These results indicate that T-oligo inhibits EC
function in a manner dependent on the dose and frequency
of administration, with the caveat that the very large amount
of oligos administered, rather that specific telomere-based T-
oligo initiated signalling may have contributed to the effect
observed. In our future experiments, we plan to examine the
effect of large and/or fractioned T-oligo doses on survival of
ECs.
3.6. Systemic Administration of T-oligo Reduces Tumor Angio-
genesis and Vessel Patency In Vivo in a SCID Mouse Xenograft
Model. In melanoma tumors inoculated into SCID mice,
we determined the effect of systemic T-oligo injection on
melanoma angiogenesis by evaluating functional and total
vessel density in tumor tissue (5 mice per group). When
tumors became palpable (2-3 mm in diameter, day 5 to 14
after inoculation) we injected T-oligo (60 nmoles/injection,
15 mg/kg) via the tail vein (IV) and injected again after
6 Journal of Oncology
(a)
(b)
+−+−
0 4824
Hours after treatment
0
50
100
150
200
250
E
2F
1
m
R
N
A
(t
im
e
0
(%
)) P < .0001 P < .0001
T-
oligo
+−+−
48240
Hours after treatment
E2F1
Actin
T-oligo
(c)
(d)
+−+−
0 4824
Hours after treatment
0
100
200
300
E
2F
1
pr
ot
ei
n
ex
pr
es
si
on
P < .02
T-
oligo
Ab-E2F1Cold+−+−
32(+)3216
654321
E2F1/DNA/E2F1
Ab supershift
E2F1/DNA
complex
(e)
(f)
(g)
+−+−
3216
Hours after treatment
0
1000
2000
3000
4000
R
D
U
P < .05
T-
oligo
+−+−
1 16
Hours after treatment
0
1000
2000
3000
4000
R
D
U
P < .01 P < .05
T-
oligo
Cold mut.+−+−+−−pr
32(−)321610
10987654321
HIF-1α /DNA
complex
Figure 2: T-oligo treatment increases E2F1 expression/activity and decreases HIF-1α DNA binding activity in MM-AN cells. Cells were
treated with 40 μM T-oligo or diluent alone and harvested at various times. (a) The pellets were examined by qRT-PCR for E2F1 mRNA
level, shown as a percent of time 0 levels (mean ± SEM) for 2 separate experiments in triplicate. (b) The pellets were also examined by
western blot analysis for E2F1 protein levels. Actin expression was used as an internal loading control. (c) Densitometric analysis of E2F1
protein expression after loading adjustment by actin, represented as a percent of time 0 levels. Results are pooled data (mean ± SEM) from
three independent experiments. (d) The DNA binding activity of E2F1 was analyzed by EMSA. No difference in E2F1 DNA binding activity
was detected between the treatment groups at 16 hours (lane 1 versus 2) but E2F1 DNA binding activity doubled in T-oligo treated cells at
32 hours (lane 3 versus 4). Specificity of bands was confirmed by preincubating the nuclear protein of T-oligo-treated cells harvested at 32
hours with ×25 cold probe (lane 4 versus 5) and by supershift of E2F1 protein/DNA and E2F1 competing antibody complex (lane 4 versus
6). (e) Quantification of the band intensity of DNA binding activity is represented as relative density untis (RDU) for both treatment groups
at 16 and 32 hours after treatment. E2F1 EMSA was repeated 2 times with similar results. (f) Nuclear protein was isolated from cells and
processed for electromobility shift assay (EMSA) for evaluation of HIF-1α DNA binding activity. Specificity of the bands was confirmed
by preincubating the nuclear protein extract of cells treated with diluent for 32 hours with ×25 cold probe (not labelled with 32P) and
mutant HIF-1α consensus sequence for 20 minutes before incubating the nuclear extracts with 32P-labeled consensus oligonucleotides. HIF-
1α EMSA was repeated 2 times with similar results. (g) Densitometric analysis of the protein/DNA complex bands for HIF-1α is graphed as
relative densitometric units (RDU).
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Figure 3: T-oligo treatment inhibits Matrigel invasion by MM-AN cells and HMVECs. MM-AN cells were treated with 40 μM T-oligo
or diluent alone. The culture medium was collected after 72 hours. The conditioned medium harvested after 72 hours was used as the
chemoattractant for the invasion assay for MM-AN and HMVECs. MM-AN cells were plated on the inserts and allowed 22 hours to move
through the pores on the membrane in the bottom of the inserts toward the medium in the lower chamber, interpreted as invasion of the gel.
The experimental inserts had a layer of Matrigel, whereas control inserts (not shown) did not. After 22 hours cells that moved through the
pores in the membrane were fixed, stained and photographed. (a) Representative images for MM-AN cells are shown. Small open circles are
the pores in the membrane, not cells. (b) The total number of cells was counted for 3 membranes for each treatment condition and graphed
as a number of cells (mean± SEM) for both treatment groups. The assay was repeated twice with identical results. (c) Representative images
for HMVECs treated as described for MM-AN above are shown. Small open circles are the pores in the membrane, not cells. (d) The total
number of HMVECs were counted for 3 membranes for each treatment condition and graphed as an average number of cells for each
treatment group (mean ± SD). The assay was repeated twice with identical results. Reductions approached but did not reach statistical
significance.
6 hours, then harvested tumors 24 hours after the second
T-oligo injections. Representative images of tumor cross-
sections were immunostained to identify all vessels as well
as functional (patent) vessels 24 hours after T-oligo injection
(Figure 6(a)). Compared to control-injected mice there was
more than ∼80% decrease (P < .002) in functional vessels
in T-oligo-injected mice (Figure 6(b)). There was also more
than ∼60% decrease (P < .004) in total vessels in T-
oligo-injected mice (Figure 6(c)). These data corroborate
our in vitro findings (Figures 4 and 5) and demonstrate
that two systemic administrations of T-oligo reduce tumor
angiogenesis and vessel patency in vivo (Figures 6(a)–
6(c)).
To determine the effect of systemic T-oligo treatment
on melanoma growth, in SCID xenograft model MM-
AN cells were injected subcutaneously in the flank. When
tumors became palpable (2-3 mm in diameter, day 5 to
14), the mice received daily systemic injections of T-oligo
(60 nmoles/injection, 15 mg/kg BID) or vehicle for 5 days
only. In control animals, tumors increased in volume from
6.96 ± 2.9 mm3 on day 6 to 88.04 ± 19.72 mm3 on day
27 (Figure 6(d), blue line). In contrast, in T-oligo treated
animals, whose tumors were the same size as in controls
on day 6 (6.48 ± 2.57) there was very little tumor growth
through day 15 (6.48 ± 2.57 versus 9.92 ± 3.8 mm3) and
thereafter a slower and statistically insignificant increase in
volume to 29.65 ± 10.47 mm3 by day 27 (Figure 6(d), pink
line). Thereby, in T-oligo-treated mice tumor growth was
inhibited (P < .003) by ∼53% after ∼4 weeks, when the
experiment was terminated. These data demonstrate that
systemic administration of T-oligo for only 5 days has a
persistent inhibitory effect on melanoma growth. We have
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Figure 4: T-oligo decreases VEGF and VEGFR-2 protein levels in normal endothelial cells. HMVEC and HUVEC were treated with 40 μM
T-oligo or diluent alone and harvested for western blot analysis over 48 hours. (a) VEGF protein expression in HMVEC. Here and elsewhere
actin expression was used to adjust the loading. (b) VEGF protein expression in HUVEC. (c) Combined densitometric analysis of VEGF
expression in HMVEC and HUVEC as a percent of time 0 levels, after loading adjustment. (d) VEGFR-2 protein expression in HMVEC. (e)
VEGFR-2 protein expression and HUVEC, and (f) Combined densitometric analysis, as in (c).
also evaluated T-oligos toxicity in several internal organs of
SCID mice 24 hours after the last IV injections (15 mg/kg
BID for 5 days). No systemic toxicity was observed in bone
marrow, liver, intestines, brain, lungs and kidneys of T-oligo-
injected mice (Figures 7(a)–7(f)).
4. Discussion
Tumor angiogenesis is essential for tumor growth and
metastasis [1]. Without active angiogenesis tumor diameter
rarely exceeds 2-3 mm [1, 48]. Angiogenesis is mediated
through release of angiogenic factors by tumor cells and
cells in the tumor stroma and microenvironment including,
but not limited to, endothelial cells [48]. We now report
that telomere homolog oligonucleotides (T-oligos) decrease
the synthesis and release of angiogenic factors by ECs
and melanoma cells, inhibit EC tubulogenesis and impede
melanoma cells and ECs from invading matrix (Matrigel).
In addition, systemic administration of T-oligos decreases
tumor vascularity in vivo.
EC migration, proliferation and differentiation are all
essential processes for tumor angiogenesis [1]. EC prolifer-
ation, in vitro tubulogenesis, and survival are all known to
be stimulated in large part by VEGF [49]. Decreased VEGF
levels or inhibition of receptor activation in ECs often corre-
late with decrease in tumor size and metastatic potential [50].
VEGF binds to the extracellular domain of the VEGFR-1 (Flt-
1) and VEGFR-2 (Flk-1), inducing receptor dimerization
and activation of tyrosine kinases by autophosphorylation,
leading to angiogenesis, increased vascular permeability, and
EC proliferation and survival [49]. It is generally accepted
that VEGFR-2 is the major mediator of these effects [51].
We found that T-oligo decreases the expression of VEGFR-
2 by HMVEC and HUVEC (Figures 4(c) and 4(f)). Other
investigators reported that receptor tyrosine kinase inhibitors
(TKIs) such as sunitinib and dasatinib reduce signaling
through the RAF/MEK/ERK pathway that is activated by lig-
and binding to angiogenic receptors like VEGFR-2, PDGFR-
β, FH-3 and c-kit [52], indirectly inhibiting tumor growth
by affecting tumor angiogenesis [52]. By reducing VEGF-R2
level, T-oligos appear to have similar effects.
Journal of Oncology 9
Diluent 40 μM ×1 80 μM ×1
120 μM ×1 40 μM ×2 40 μM ×3
(a)
40
μ
M
×3
12
0
μ
M
×1
40
μ
M
×2
80
μ
M
×1
40
μ
M
×1
D
ilu
en
t
0
5000
10000
15000
20000
Tu
be
le
n
gt
h
(p
ix
el
s)
P = NS P = NS
P < .03 P < .001
P < .0001
P = NS
(b)
Figure 5: T-oligo treatment inhibits EC tubulogenesis in vitro. HMVEC cells were plated on Matrigel in four-well chamber slides and treated
in triplicate with T-oligo or diluent alone, as described in the text. (a) All representative images are taken 22 hours after plating cells into
chambers, the time of biggest differences among treatment conditions. (b) The length of tube-like structures was quantified as total average
tube lengths per visual field from 3 separate chambers for each treatment condition. The differences in the length of tube-like structures were
quantified (in pixels) in at least 3–5 representative photographs per chamber/treatment condition using computer-assisted image analysis.
VEGF also induces leakage within tumor vessels, allowing
tumor cells to infiltrate blood vessels and migrate into the
blood stream [53]. Hence, changes in angiogenic factors
even early in tumor formation can affect metastasis and
spread [53] and inhibiting VEGF production by T-oligos
would be expected to reduce the metastatic potential of
tumor cells [53]. Additionally, increased blood vessel per-
meability within the tumor may interfere with adequate
delivery and retention of chemotherapeutic agents [54, 55].
Indeed, certain antiangiogenic agents that prevent tumor
vessel leakage (a phenomenon called “vessel normalization”)
were shown to enhance the delivery of chemotherapeutic
agents into tumors [56]. Thus, combination treatment with
antiangiogenic factors together with conventional chemo-
therapeutic agents may be superior to using the latter alone.
Furthermore, because VEGF is likely required for migration
and recruitment of ECs, T-oligo-me diated VEGF reduction
would also likely decrease the number of blood vessels in
the tumor [1, 6]. Our present findings suggest that T-oligos
may induce potent antiangiogenic effects, enhancing their
attractiveness as a therapeutic option for cancer.
In addition to VEGF and its receptors, angiopoietin 1 and
2 (ANG-1 and ANG-2) and their tyrosine kinase receptor
Tie-2 have been identified as major players in the processes
of growth and remodelling of tumor vasculature [57, 58].
ANG-1 activates the Tie-2 signalling pathway [58]. Although
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Figure 6: T-oligo decrease tumor angiogenesis and melanoma tumor volumes in mouse SCID xenografts. (a) Representative images of
6 μm tumor cross-sections immunostained with CD31 (green) and TopRo-3 (blue-nuclei) and perfused in vivo with BS-1 lectin (red),
to determine tumor microvascular density (MVD) per high power field (HPF) ×40 magnification. Both functional and total vessels were
examined in 5 mice/group. Arrows indicate CD31 (+) vessels that are considered nonfunctional (not perfused) whereas arrowheads indicate
double (+) BS-1 lectin/CD31 vessels that are considered functional (perfused in vivo). (b) Percent functional vessels (red-BS-1 lectin staining)
in T-oligo injected mice, taking MVD in vehicle injected mice as 100%. (c) Percent total vessels (green-CD31 staining) in T-oligo injected
mice, taking MVD in vehicle injected mice as 100%. (d) SCID mice were injected with MMAN cells into the flank. T-oligo or vehicle was
injected daily for up to 5 days when tumors were first palpable (2-3 mm diameter). Average tumor volume/animal was recorded over 4-weeks
in 5-6 mice/group.
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Figure 7: Evaluation of T-oligos toxicity in internal organs of SCID mice 24 hours after the last IV injection (15 mg/kg BID for 5 days). (a)
Bone marrow, displaying a mixture of myeloid and erythroid precursor cells as well as plasma cells. Scattered megakeryocytes are also present.
There is no evidence of bone marrow suppression or toxicity. (b) Liver lobule with a central vein surrounded by hepatocytes. The cells display
a fixation artifact but otherwise appear normal. There is no evidence of cellular necrosis or apoptosis. (c) Jejunal mucosa displaying normal
arrangement of villi lined by tall columnar cells. Both the mucosa and the submucosa appear normal. Fragments of normal pancreatic acinar
tissue are seen in the bottom left of the image. (d) Section of the brain showing normal brain architecture with typical neuronal ganglia and
scattered small dark glial cells in a pink neuropil background. (e) Normal lung tissue displaying multiple alveoli as well as bronchioles lined
with cuboidal epithelial lining. (f) The kidney displays two normal glomeruli that are surrounded by tubules with cuboidal epithelium.
under certain conditions ANG-2 may inhibit ANG-1 effect,
in an in vivo mouse model for melanoma [59] and in
glioma cells [60] increased expression of ANG-2 is thought
to stimulate angiogenesis. Another angiogenic factor, HIF-
1α, a transcription factor that is activated by hypoxia, exerts
its effect by upregulating VEGF levels. We found that T-
oligo treatment inhibits HIF-1α activity and ANG-1 and
ANG-2 expression in melanoma cell line and decreases VEGF
synthesis secretion in these cells, strongly suggesting that T-
oligo-mediated effects on tumor angiogenesis are transcrip-
tional and ultimately affect several angiogenic molecules.
Our laboratory has previously shown that T-oligo
increases p73 level in the p53 null MM-AN cells and
that blocking p73 expression by RNAi decreases T-oligo-
induced apoptosis in these cells [11]. Like p53, p73 is
known to inhibit angiogenesis, primarily through VEGF
down-regulation [34]. Therefore, we assume that in MM-
AN cells T-oligo decreases VEGF production, in addition to
its effect on HIF-1α, by activating p73 through induction
of E2F1. However, in cells with functional p53, we assume
that T-oligo-induced p53 and p73 would cooperate to
inhibit angiogenesis. Furthermore, E2F1 is known to induce
apoptosis in part by its effect on p73. Thus, induction
of E2F1 by T-oligos [11] also contributes to tumor cell
apoptosis. E2F1 is reported to be upregulated by active
(phosphorylated) ATM [61]. We have previously shown that
T-oligo treatment activates (phosphorylates) ATM [21, 27].
Moreover, the E2F1 promoter contains binding sites for
E2F1 [62]. We therefore suggest that T-oligo regulates E2F1
first via ATM-mediated phosphorylation of E2F1 [61] and
that E2F1 then further transcriptionally upregulates E2F1 by
binding to its own promoter. Indeed, we show that T-oligo
increases E2F1 mRNA and protein levels as well as its DNA
binding activity in human MM-AN melanoma cells, further
confirming our previous finding that E2F1contributes to T-
oligo effects [11].
The T-oligos used in the present experiments have phys-
iologic readily hydrolysable phosphodiester linkage, unlike
for example antisense DNA in which phosphorothioate or
other nonhydrolyzable linkage is employed to increase the
molecule’s half-life (T 1/2). Hydrolyzable linkage is required
for initiation of T-oligo signalling [22] and, despite the
known short T 1/2, approximately 4–6 hours in serum-
containing medium for a 12-base 100% telomere homolog
[38], nevertheless this allows for the cellular responses
observed in the present and previous experiments to evolve
over 3–5 days [11, 13, 19, 21, 22, 24–28]. This may reflect
the fact that at least in vitro T-oligos rapidly enter the
nucleus [11, 22, 24, 27] and that, once in the nucleus,
such oligos have a far longer T 1/2 [63]. The efficacy of
these presumptively short-lived T-oligos may also reflect
the likelihood that, after interaction of the oligos with the
Werner protein and formation of DNA damage-like foci at
telomeres [22], signalling through the DNA damage response
pathways may continue even if the T-oligos have been
hydrolyzed, at least through 48 hours at which time the DNA
damage foci can still be observed by immunohistochemistry
[22].
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In earlier studies, we have shown that T-oligos inhibit
tumor growth in SCID mouse models by inducing cell cycle
arrest, differentiation, apoptosis, and senescence [13, 15, 27].
We now show that T-oligos also inhibit angiogenesis. Angio-
genesis inhibition encompassing both ECs and melanoma
cells, in combination with other T-oligo-mediated anti-
tumor effects [11, 13, 22, 25, 27], likely combine to
significantly decrease melanoma burden in established SCID
mouse models, as reported in our earlier publications
[13, 27]. These multiple diverse responses are all mediated
through activation and/or upregulation of DNA damage
response proteins. They are thus reminiscent of the less
complex but very well characterized bacterial SOS response,
a genome-protective mechanism that enhances survival of
prokaryotic organisms in the face of DNA damage [14]. The
telomere-based DNA damage-like signalling initiated by T-
oligos may be viewed as an evolutionarily perfected parallel
mechanism in mammalian cells that addresses the threat to
genomic integrity posed by malignant transformation [64].
In summary, the present paper indicates that T-oligos
exert multiple antiangiogenic effects. These data reinforce
prior evidence that T-oligo therapy may offer a powerful new
approach to treatment of human primary melanoma and
possibly other human malignancies, with several conceptual
advantages over the currently lionized targeted therapy
approach [64].
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